TDC
PVLA

Thompson Davis & Co’s Palvella Therapeutics PVLA Stock Holding History

Thompson Davis & Co’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-281
Closed -$62K – 1263
2015
Q2 		$62K Buy
+281
New +$61.8K 0.07% 270

Other funds holding PVLA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Thompson Davis & Co's PVLA Position: Q3 2015 in Review

Thompson Davis & Co sold out of Palvella Therapeutics (PVLA) in Q3 2015, closing a stake of 281 shares — an estimated $62K sold.

Thompson Davis & Co first reported a position in PVLA in Q2 2015 and held it in 1 quarter. The position peaked at $62K in Q2 2015. 13 funds tracked by Wall St. Rank hold PVLA as of Q3 2015.

  • Thompson Davis & Co reported no remaining Palvella Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Thompson Davis & Co sold 281 Palvella Therapeutics shares in Q3 2015, an estimated $62K.
  • Thompson Davis & Co first reported a position in Palvella Therapeutics in Q2 2015 and held it in 1 quarter.
  • Thompson Davis & Co's Palvella Therapeutics position peaked at $62K in Q2 2015.
  • 13 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2015.

Based on Thompson Davis & Co's 13F filing for Q3 2015, filed 30 Oct 2015.